Podcasts about Pharma

Jordan Sather and Nate Prince deliver a packed episode of MAHA News, kicking off with the CDC's explosive website update acknowledging that claims of “no link” between vaccines and autism are not evidence-based, triggering absolute meltdown across legacy media, pharma loyalists, and blue-state health bureaucracies. The hosts track the political fallout, RFK Jr.'s direct role in ordering the change, and the wave of scientists now admitting long-ignored biologic mechanisms worth investigating. From Bhattacharya and Makary's blunt critiques of captured institutions to Robert Malone exposing the financial corruption inside the AAP and ACIP, the guys highlight a medical landscape finally cracking open. Jordan and Nate also dive into SSRIs, microbiome destruction, gut health, antibiotic overuse, and the soaring chronic-illness rates no one in the old regime wants to talk about. The episode closes with a fiery breakdown of SNAP as corporate welfare, revealing how billions in taxpayer dollars funnel straight into Coca-Cola, Frito-Lay, Walmart, and Big Food, while politicians pretend it's about “feeding the poor.” A fast, funny, and fiercely honest episode charting the scientific and political shifts reshaping U.S. health policy.

P.M. Edition for Nov. 21. It's mostly tech companies that have hit the milestone of a $1 trillion valuation. As WSJ Heard on the Street columnist David Wainer explains, Eli Lilly's entrance into this elite club is for a completely different reason: weight-loss drugs. Plus, New Mexico is one of the poorest states in the U.S., but it's planning to spend millions of dollars per year to be the first state to offer universal childcare. We hear from WSJ economics reporter Harriet Torry about how the plan will work, and what critics say. And now that the U.S. has presented its 28-point peace plan to Ukraine, President Trump says he expects an answer by Thanksgiving, leaving Ukrainian President Volodymyr Zelensky with what he calls a very difficult choice. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it's a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the right company at just the right time. Get it right, and you walk away with a clear path forward and the cash to fund it. But get unlucky and you might find yourself with few options in the New Year.This year, we decided to follow one biotech heading into their first BIO-Europe partnering conference. We met with DISCO Pharma three times over the last month to follow their BIO-Europe journey:Before the event to learn about the science behind DISCO and understand what their goals were heading into BIO-Europe. At the event itself to talk about how the partnering meetings had been going and how the event had shaped up for DISCO. A week after BIO-Europe had closed, diving into the follow-up activities and learning about the next steps for this German biotech.I hope you enjoy my conversations with Ajla Hrle, Chief Business Officer at DISCO, and this behind the scenes look at BIO-Europe from an innovator's perspective.02:25          Preparing for BIO-Europe16:51           On the floor at BIO-Europe22:23          Following up from BIO-EuropeInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: BIO-Europe partnering: Australian biotech companies share their experiencesPractical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepBiotech in Vienna: a budding life science hub 

Wingman Epstein - 11.19.2025 - #893 BestPodcastintheMetaverse.com Canary Cry News Talk #893 - 11.19.2025 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com   Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers LX Protocol BARON of the Berrean Protocol*** Trevor G*** Felicia D***   Producers of TREASURE (CanaryCry.Support) Jeremy M, Monica, Cage Rattler Coffee   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   EPSTEIN "Almost" Unanimous Vote to release Epstein files (NBC) Sttacey Plaskett was "Coached by epstien during Cohen Hearing. (NYT) Clip: Jamie "Defends" Plaskett saying "Theres a lot more to come out"  Clip: Larry summers apologizes for epstein connection in his college class Epstein was Larry Summers' "Wingman" (INDY)   PHARMA The Rise and Fall of "Osterich Pharma" (The Aatlantic)    POLYTICKS Forget Joe Rogan. The Next Big Podcast Bro Is in the Senate. (Politico)   EXECUTIVE PRODUCERS TALENT/TIME END

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dans cet épisode de Cheminements, je reçois Cyril Sarrauste, patient partenaire et co-responsable de Mon Réseau Cancer Colorectal, et Alexandre Iovine, Medical Advisor chez Servier. Ensemble, nous abordons un sujet encore trop peu discuté dans les parcours de soins : la sexualité pendant et après un cancer colorectal. Portée par l'association Patients en Réseau, une initiative inédite a vu le jour : un questionnaire construit par et pour les patients. Ce projet vise à mieux comprendre les besoins, les freins et les réalités vécues autour de la sexualité. Nous explorons aussi la manière dont ces retours peuvent nourrir l'évolution des pratiques médicales. Enfin, nous évoquons le rôle des collaborations entre patients et laboratoires pour faire avancer les lignes.Axes abordés dans l'épisode :Pourquoi et comment parler de sexualité dans le cadre du cancer colorectalLa genèse et les objectifs du questionnaire porté par l'association Patients en RéseauLes retours des patients et les enseignements majeurs recueillisLa réception de ces résultats par les professionnels de santéL'impact potentiel de ces données sur l'évolution des pratiques médicalesLe rôle des associations dans l'intégration de la qualité de vie au parcours de soinsCet épisode est enregistré dans le cadre de la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui aura lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que cette journée s'écoutera aussi ! Des épisodes exclusifs du podcast Cheminements seront enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui viendront raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/

In this episode of the Medical Sales Podcast, Samuel sits down with Jennifer Jones, a former top Purdue Pharma rep who lived through the rise, collapse, and aftermath of one of the most controversial chapters in pharmaceutical history. Jennifer opens up about her early passion for pain management, what reps were taught, how Q12 vs Q8 dosing shaped patient experiences, and the moment Purdue shut down while she was on vacation. She shares the emotional toll of grand jury testimony, FBI investigations, and watching once-trusted leaders face prison time, while also revealing the patients and physicians who were genuinely trying to do the right thing. From navigating "pill mill" stereotypes to seeing pain doctors wrongly targeted, Jennifer gives a raw, inside look at the complexities reps faced long before the media headlines. Now a thriving medical device rep in cardiology, she talks about rebuilding her career, stepping into entrepreneurship, and rediscovering her purpose in healthcare. This is one of the most honest conversations ever recorded about pharma, pain management, and what it means to survive, grow, and lead in medical sales.   Connect with Jennifer Jones: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

In this episode of Virtually Anything Goes, we dive deep into the remarkable leadership journey of Chris Knerr, VP of Strategy (MedTech) at Veeva Systems, Chris is a leader whose path spans entrepreneurship, Fortune 500 executive roles, and a lifelong love of philosophy.Chris shares how his early academic pursuit of philosophy shaped his thinking, his leadership style, and his ability to navigate complex human dynamics inside some of the world's largest organizations. From his 14-year rise at Johnson & Johnson to building and exiting his own company to guiding digital transformation for global medtech leaders, Chris opens up about the turning points that defined his professional identity.You'll hear candid stories from inside high-stakes transformation programs, including the pivotal moments where mentors challenged him, encouraged him, or changed the course of his career with a single sentence. Chris reflects on the transition we all face when moving from individual contributor to leader: the moment you stop “knowing everything” and start empowering others who may know more than you. His honesty about fear, confidence, and learning to “lighten up” makes this one of the most relatable leadership conversations in the series.We also explore the political realities of leadership, how to spot the difference between visionaries and survivors at senior levels, and the underestimated role of luck and timing in every success story. Chris brings a rare blend of philosophical depth and practical experience as he unpacks what leaders really need to understand about influence, organizational behavior, and decision-making under pressure.Finally, the conversation shifts into AI, autonomy, and the future of leadership. Chris shares thoughtful, and sometimes provocative, insights on how algorithms shape human choice, what worries him most about invisible automation, and how leaders should prepare for a world where AI is embedded in every workflow.If you're a leader, aspiring leader, or simply fascinated by how people grow, decide, and influence at scale, this episode is a must-listen. Subscribe for more conversations that go beyond the surface.Chris Knerr is the VP Technology Strategy (MedTech) at Veeva Systems. He is a 20+ year multi-disciplinary Life Sciences industry veteran (Med Device, Pharma, Consumer OTC) driving change and key results in growth, operating leverage, differentiation and competitive position at enterprise scale; Chris is a former J&J VP, has founded and exited his own company, and his experience spans Fortune 50, management consulting, portfolio company, and tech start-ups.Chris is also an industry thought leader and writer; Cornell MBA; frequent guest lecturer at Cornell MBA program in Digital Strategy & Strategic Brand/Product ImmersionsConnect with Chris Knerr on Linkedin: https://www.linkedin.com/in/chrisknerr/Lev Cribb is the Founder and Managing Director of Made To See, a UK-based Video and Livestreaming Agency, specialising in the strategic and tactical use of video across B2B organisations. Lev is also the host of the Virtually Anything Goes podcast.Made To See: https://madetosee.com/For more information, content, and podcast episodes go to https://www.madetosee.com or our YouTube channel  ⁨@madetoseemedia⁩  

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What's on your mind? Let CX Passport know...Curiosity from the lab. Creativity from marketing. Transformation across a global pharma giant. Trina Di Giusto brings a scientist's discipline and a storyteller's instinct to CX. She explains how decentralized teams can still create harmony, why AI is tempting but rarely the fix, and what it takes for change to stick in a complex organization.5 Insights From This Episode • Scientific thinking becomes a CX advantage… methodical meets imaginative • Pharma customers span patients, providers, payers, and regulators • Delegation without orchestration leads to fragmentation • AI only works when the underlying process is healthy • Real change lasts when vision, skills, incentives, resources, and action alignCHAPTERS 00:00 Meet Trina from Basel 01:27 When science meets storytelling 03:47 Logic in a creative world 05:50 Blurring science and marketing 08:29 Defining CX in pharma 11:18 Delegation versus orchestration 13:57 First Class Lounge 18:01 Why tech is not the fix 22:51 What change management really requires 25:56 Lessons across six transformation cycles 28:06 Final takeaways and how to reach TrinaGuest Links LinkedIn: https://www.linkedin.com/in/trinadigiusto/Listen, Watch, Newsletter Listen: https://www.cxpassport.com Watch: https://www.youtube.com/@cxpassport Newsletter: https://cxpassport.kit.com/signupI'm Rick Denton and I believe the best meals are served outside and require a passport.Disclaimer: This podcast is for informational and entertainment purposes only. The views and opinions expressed are those of the hosts and guests and should not be taken as legal, financial, or professional advice. Always consult with a qualified attorney, financial advisor, or other professional regarding your specific situation. The opinions expressed by guests are solely theirs and do not necessarily represent the views or positions of the host(s).

What if one decision could make or break your drug's success? Join Charles River's Sarah Gould as she unpacks the high-stakes, emotion-filled world of species selection—and why it's about so much more than science. Discover how this critical choice shapes safety, speeds development, and drives innovation in today's evolving research landscape.Show Notes Alternative Methods Advancement Project  | Charles River Animals in Research  | Charles River Research Models and Services | Charles River Research Animals Models | Charles River 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

La peau est le plus grand organe du corps : elle recouvre toute notre surface, représente en moyenne 1,5 à 2 m² et pèse plusieurs kilos. Elle assure des fonctions vitales : barrière contre les UV, microbes, toxiques et traumatismes, thermorégulation et maintien de l'équilibre hydrique, ainsi que sensorialité via un réseau nerveux riche. Dans cet épisode, nous allons parler de peau, mais pas que.Et si elle nous protège au quotidien, elle peut aussi souffrir, notamment sous l'effet des traitements du cancer. Je reçois trois invités engagés pour parler d'un sujet encore trop méconnu : les effets indésirables cutanés liés aux traitements contre le cancer. La peau, en première ligne face aux thérapies, peut devenir le miroir visible de la maladie, avec des conséquences physiques, psychologiques et sociales. Le Dr Jean-Matthieu L'Orphelin, dermatologue au CHU de Caen, nous éclaire sur ces toxicités souvent invisibilisées dans les parcours de soins. Laure Guéroult-Accolas, fondatrice de Mon Réseau Cancer, partage son expérience de patiente et son engagement pour une meilleure information. Alexandre Couttet, du groupe Pierre Fabre, nous présente les initiatives de prévention et d'accompagnement menées par l'industrie. Ensemble, nous explorons comment prévenir, prendre en charge, et surtout accompagner les patients face à ces effets. Dans cet épisode, nous abordons :Les différents types de toxicités cutanées et leur impact sur la qualité de vieLe rôle des patients, soignants et industriels dans la prévention et la prise en chargeLe programme Act For Skin de Pierre Fabre et les solutions dermo-cosmétiquesLa dimension sociale et psychologique des effets indésirables visiblesL'importance d'une approche globale de la peau dans les parcours de soinsLes collaborations entre hôpitaux, associations et laboratoires pour améliorer l'accompagnementCet épisode est enregistré dans le cadre de la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui aura lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que cette journée s'écoutera aussi ! Des épisodes exclusifs du podcast Cheminements seront enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui viendront raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio's hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today's market. Timecodes: 0:00 Introduction0:38 Why Formation Bio? Origins and Mission1:12 The Real Bottleneck: Clinical Development4:56 Formation Bio's Business Model7:50 Picking Winners: The Art and Science of Drug Selection11:54 First-in-Class vs. Best-in-Class Strategies14:04 Overcoming Regulatory and Market Challenges17:26 The Stakes: Can We Approve More Drugs?19:07 How Formation Bio Cuts Cost and Time21:43 AI's Role in Drug Development25:10 The Future: From 50 to 500 Drug Approvals?35:18 Global Competition: The Rise of China39:28 The Path Forward: Data, Regulation, and Access41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiuFind Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: https://x.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zListen to the Raising Health Podcast on Spotify: https://open.spotify.com/show/4fjb8YTzHDuPBgDXc3ElkRListen to the Raising Health Podcast  Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/raising-health/id1529318900Follow our host: https://x.com/eriktorenbergPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The best biotech and pharmaceutical innovations mean nothing if they can't be protected—and protected fast. Our next guest, Josh Goldberg, is solving this challenge as co-managing partner at Nath, Goldberg & Meyer, the #1 ranked patent law firm for biotech and pharmaceutical technologies. With nearly three decades of IP law experience and a unique background as a lab researcher, Josh brings an insider's understanding of how innovation actually happens. He's helped industry leaders like Amgen, Takeda, and GlaxoSmithKline turn breakthrough treatments into patent-protected portfolios—often in under a year instead of the typical four-year timeline. Driven by a passion for focus and strategic IP timing, Josh shares his pioneering approach to biotech and pharmaceutical patent prosecution. Join us to discover how smart IP strategy drives licensing power, regulatory success, and company valuation. Let's go!Episode Highlights:Focus drives success – Companies fail by trying to do everything at once; staying deliberate and focused is key to making real impactOne-year patent timelines vs. four years – Josh uses USPTO's Track 1 program to secure patents in record time, improving fundraising and M&A positioningClient-centered approach wins – Listening to unique client needs instead of one-size-fits-all strategies earned the firm its #1 rankingDiagnostic patents are back – New USPTO Director signals the patent office is "open for business" again after a decade of restrictionsScientist turned patent attorney – Josh's lab background gives him insider understanding of how innovation actually happensAbout our Guest: Joshua is the patent attorney innovation-driven pharmaceutical companies call when they need to turn complicated technologies into protected assets in record time.As co-managing partner at Nath, Goldberg & Meyer—the #1 ranked patent law firm for biotech and pharmaceutical technologies in both 2024 and 2025—Joshua leads IP efforts across industries like biotech, pharma, agriculture, renewable energy, and advanced materials. Whether it's a blockbuster acne treatment like DUAC, a vitamin D analog lotion like Sorilux, OTC solutions like Salonpas and Germagic, or a leading drug used to reduce stomach acid and treat conditions like GERD, ulcers, and heartburn—like Protonix—Joshua helps turn high-stakes R&D into patent-protected portfolios, often in under a year instead of the typical four-year timeline.Though his climate and agricultre IP expertise has made him famous as the “green patent guy,” Joshua moves between disciplines skillfully and has helped industry leaders like Amgen, Takeda, Guilford Pharmaceuticals, Mayne, and Stiefel Laboratories (which was acquired by GlaxoSmithKline) build pharma portfolios that hold up under investor, acquirer, and FDA scrutiny.His journey didn't begin in IP law, but in the lab, researching experimental pharmaceutical delivery systems. It gave him an edge most attorneys don't have: understanding how innovation actually happens, and how to protect it without slowing a business down. Links Supporting This Episode: Nath, Goldberg & Meyer Website: CLICK HEREJoshua Goldberg LinkedIn page: CLICK HERENath, Goldberg & Meyer LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page:...

Do you have a medical sales interview coming up?Pharma, medical device, diagnostics, or biotech… this video will help you stand out and win the offer. This industry is highly competitive, and the candidates who succeed do more than answer questions. They own the interview. What you will learn in this episode: - How to make a powerful first impression with “Tell me about yourself”- How to walk through your resume like a top performer- How to connect your background to the company's mission, product, and impact on patients- How to communicate what makes you unique without clichés- How to discuss strengths and weaknesses with strategy and confidence- How to show cultural fit and real motivation- How to navigate the salary question without losing momentum- How to close strong and leave a memorable impressionEverything I teach comes from real hiring experience in medical sales, including pharma and oncology. After this video, you will know exactly how to prepare with purpose, communicate like a professional, and outperform people who may have more experience on paper.If you are serious about getting into or advancing in medical sales, you are in the right place.Subscribe to get coaching, tools, and real interview strategies that help you win the offer.Preparation creates confidence. Confidence wins offers.Learn more about coaching and career support at https://medicalsalesu.com/

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expand their capabilities and portfolios. Similarly, Pfizer's finalized acquisition of Metsera after a fierce bidding war with Novo Nordisk underscores the importance of securing valuable assets to strengthen positioning in critical therapeutic areas, such as obesity treatment, where demand continues to rise.Regulatory milestones remain at the heart of industry progress. Organon and Henlius's Poherdy recently received FDA approval as a biosimilar to Roche's Perjeta, offering a new treatment avenue for HER2-positive breast cancer patients. This approval is noteworthy as biosimilars play an essential role in oncology by providing similar efficacy to original biologics but at reduced costs, thereby enhancing healthcare affordability and accessibility. In Europe, the EMA's Committee for Medicinal Products for Human Use has endorsed several innovative drugs, including Otsuka's Dawnzera for hereditary angioedema and Lilly's Inluriyo for certain cancer types. These endorsements reflect the growing pipeline of treatments addressing both rare genetic disorders and widespread diseases.Merck & Co.'s acquisition of Cidara Therapeutics for $9.2 billion underscores a strategic pivot towards bolstering its antiviral portfolio. This deal is particularly significant given Cidara's promising influenza antiviral candidate, initially abandoned by Johnson & Johnson. In an era where infectious diseases pose ever-evolving challenges, Merck's investment in antivirals reflects a commitment to advancing therapeutic solutions in this crucial area.However, drug development's inherent uncertainties were highlighted by Bristol Myers Squibb and Johnson & Johnson's joint anticoagulant venture, which faced termination due to a Phase 3 trial failure. This setback emphasizes the challenges and risks entailed in developing novel therapeutics, particularly within high-stakes areas like cardiovascular health.Leadership changes can significantly impact corporate strategy, as seen with Bavarian Nordic following an unsuccessful private equity takeover attempt. Such shifts can influence investor confidence and reshape strategic directions.Investment trends also paint an optimistic picture for innovation within the sector. European life sciences investor Medicxi's successful raising of €500 million signifies robust financial support for biotech ventures. This influx of capital is vital for propelling early-stage research and development efforts across Europe, fostering breakthroughs in chronic and rare disease treatments.In terms of scientific innovation, advancements in bispecific antibody production through AI/ML-driven molecular design promise higher yields and enhanced quality. These technological innovations could revolutionize complex biologics manufacturing, potentially accelerating timelines and expanding therapeutic possibilities.The regulatory landscape is seeing significant activity as well. Notably, FDA officials introduced a novel pathway aimed at accelerating gene editing therapies' development and approval. By facilitating faster market entry for personalized medicines, this regulatory innovation could pave the way for treatments tailored to individual genetic profiles.Kyowa Kirin's collaboration with Kura Oncology reached a milestone with FDA approval for an oral medication targeting acute myeloidSupport the show

Send Zorba a message!ProPublica (an independent, non-profit news organization) recently reported on the FDA's handling of potential safety issues concerning generic drugs we get from overseas manufacturers. Some of their findings include:·     For decades, the FDA has blacked out the names of generic drugs on inspection reports for foreign factories that were found to have safety and quality violations. ·     This has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe. You can find the ProPublica article here(Recorded Nov 10, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest. The conversation covers: Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the company's trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDA's move away from animal testing and offering something game-changing in the CMC and GMP space The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

Send Zorba a message!ProPublica (an independent, non-profit news organization) recently reported on the FDA's handling of potential safety issues concerning generic drugs we get from overseas manufacturers. Some of their findings include:·     For decades, the FDA has blacked out the names of generic drugs on inspection reports for foreign factories that were found to have safety and quality violations. ·     This has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe. You can find the ProPublica article here(Recorded Nov 10, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Die EU hat den Covestro-Deal mit Adnoc freigegeben. Nun muss noch die Bundesregierung zustimmen. Und: Bei Novo Nordisk sorgt ein Aufsichtsratsumbau für Unsicherheit.

“What you have to do in a market like that, where it’s highly genericized, is first you have to have a clinical differentiation,” says Richard Lowenthal, CEO of ARS Pharmaceuticals. “You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that’s very simple — it’s easy to carry, it’s very easy to use.” In this episode of Vanguards of Health Care, Richard sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.See omnystudio.com/listener for privacy information.

Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.The ultimate unholy union is government and healthcare. President Trump has put out some words on government and healthcare, and President Trump, is a good friend of big Pharma.Episode Links:Democrat Senator Peter Welch on Obamacare: "We did fail to bring down the cost of healthcare."American doctor goes over how Barack Obama destroyed American HealthcareObamacare is only 7% of Americans. Literally almost 100% of Americans need relief from their health care policy premiums, not just 7%. We need to have free market solutions that bring down the cost of health care for every American, not just the 7%.The Danish Cow Crisis: Bill Gates, “Bovaer,” and the War on Nature. In Denmark, farmers are raising alarms after a new climate-driven feed additive called Bovaer became mandatory on October 1, 2025.Virtually everything that Obama promised about Obamacare was a lie. Now the country is stuck dealing with the ramifications. Instead of taking responsibility, Democrats have shut down the government and are demanding that Republicans fix what they broke.

Canadian journalist Nora Loreto reads the latest headlines for Wednesday, November 12, 2025.TRNN has partnered with Loreto to syndicate and share her daily news digest with our audience. Tune in every morning to the TRNN podcast feed to hear the latest important news stories from Canada and worldwide.Find more headlines from Nora at Sandy & Nora Talk Politics podcast feed.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-news-podcast--2952221/support.Help us continue producing radically independent news and in-depth analysis by following us and becoming a monthly sustainer.Follow us on:Bluesky: @therealnews.comFacebook: The Real News NetworkTwitter: @TheRealNewsYouTube: @therealnewsInstagram: @therealnewsnetworkBecome a member and join the Supporters Club for The Real News Podcast today!

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT's US deals and activism correspondent Oliver Barnes walks through the tussle that's involved lawsuits, public barbs and political drama. Clips from CNBC, Pfizer, Yahoo Finance- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading and listening:Weight-loss wars: $10bn hostile battle pits Pfizer against Novo NordiskPfizer shows hardball mettle needed to win in 2025 M&AThere is only one winner in the Pfizer Novo Nordisk showdownOzempic's unconventional origins- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Hosted on Acast. See acast.com/privacy for more information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Robotikfantasie bei Xpeng, die Weihnachtsüberraschung von FedEx und den Shutdown-Schub für Pharma. Außerdem geht es um Merck, Johnson&Johnson, Amgen, CoreWeave, Nvidia, Softbank, Micron, Oracle, Palantir, Merck KGaA, Siemens Healthineers, UPS, Bayer, Amazon, Alphabet, Microsoft, iShares Core MSCI World ETF (WKN: A0RPWH), Amundi MSCI All Country World ETF (WKN: LYX00C), Vanguard S&P 500 ETF (WKN: A1JX53), iShares Nasdaq 100 ETF (WKN: A0YEDL), Amundi Core Stoxx Europe 600 ETF (WKN: LYX0Q0), Xtrackers MSCI Japan ETF (WKN: DBX1MJ), iShares MSCI China ETF (WKN: A2PGQN), Xtrackers Artificial Intelligence & Big Data ETF (WKN: A2N6LC), Alphabet, Apple, Nvidia und Palantir, Euwax Gold II (WKN: EWG2LD), Xetra Gold (WKN: A0S9GB), Global X Infrastructure ETF (WKN: A40E7B), Vanguard FTSE All World (WKN: A2PKXG), SPDR MSCI All Country World ETF (WKN: A1JJTC), Xtrackers MSCI Emerging Markets ETF (WKN: A12GVR), Vanguard FTSE Emerging Markets ETF (WKN: A2PLTC), iShares EUR High Yield Corporate Bond (WKN: A2DUCZ) und PIMCO Euro Short-Term High Yield Corporate Bond (WKN: A2DLP1). Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

AI and GLP-1s.As a healthcare reporter, we often get asked: ‘What are the top industry trends that brand and agency leaders are most focused on?' And that's our response: AI and GLP-1s.Luckily for you, this week's episode provides a taste of both.Our feature interview this week is an in-person conversation between managing editor Jack O'Brien and Curtis Sparrer, principal and co-founder of Bospar PR.Curtis flew in from San Francisco to preview the MM+M tracks at Haymarket Media's second annual AI Deciphered conference on Thursday. (Please note, last minute tickets are still available!)For Trends, pharma editor Lecia Bushak and editor-at-large Steve Madden get you up to speed on the week that was in GLP-1-land: from Pfizer muscling out Novo Nordisk for obesity drug developer Metsera, to the White House's drug pricing deal with Novo and Eli Lilly.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In search of the next miracle “cure,” Big Pharma has become very proficient at developing highly effective and obscenely profitable drugs aimed at treating rare diseases (think $750,000 per year) at the expense of ignoring newer, safer and effective treatments geared to a wider audience.Alex Martinez, CEO and cofounder of Intrinsic Medicine, shares his amazing journey from being a healthcare attorney who witnessed the good, bad and mostly ugly in Big Pharma to revolutionizing how we care for the human microbiome this week on Spirit Gym. Learn more about Alex's Intrinsic Medicine company at his website. Find him on social media via LinkedIn.Show Notes8:47 “The mission was attractive to me.”12:27 Alex got the education he needed while ground-truthing at the same time.20:50 Why is Big Pharma's disproportionate focus on drugs that treat rare diseases?30:16 Evolutionary biology.39:07 Alex is a very intelligent vegetable.44:42 Human milk oligosaccharides (HMOs) formulated with information molecules.51:53 The fecal transplant isn't new science.1:06:46 Freediving helped Alex look inward toward the microbiome.1:13:26 “What's inside of us is all around us.”1:25:05 The HMOs in breast milk serve as training mechanisms in a baby's gut.1:36:05 Is it possible that HMOs could work one day like fecal transplants?1:44:47 Where do these HMOs originate?1:50:33 Formulating infant formulas that aren't inflammatory should be the norm but aren't.2:07:29 Creating an ethical regenerative business by integrating humanity into it.2:12:49 Humans are so good at finding comfort in dis-ease.2:25:34 Where probiotics went wrong.Resources BifidobacteriumFructooligosaccharides (FOS)Paul's Living 4D conversation with Dr. Nathan RileyThe Abdominal and Pelvic Brain by Byron RobinsonFind more resources for this episode on our website.Music Credit: Meet Your Heroes (444Hz), Composed, mixed, mastered and produced by Michael RB Schwartz of Brave Bear MusicThanks to our awesome sponsors:PaleovalleyBIOptimizers US and BIOptimizers UK PAUL15Organifi CHEK20Wild PasturesKorrect SPIRITGYMPique LifeCHEK Institute We may earn commissions from qualifying purchases using affiliate links.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What's on your mind? Let CX Passport know...Pharma and CX… not exactly two words you hear together often. But what happens when customer experience thinking meets healthcare? Silvi Haldipur has lived it. From personal experience to transforming patient, provider, and payer experiences at GSK and Merck, she's proving that empathy and data can coexist to truly save lives.5 Insights from This Episode • CX in pharma isn't impossible… it's essential. Silvi shares how she turned a deeply personal healthcare experience into her mission for better patient outcomes. • Beyond ads and emails… why support, not slogans, is what patients really need. • What pharma can learn from design thinking, ethnography, and on-the-ground empathy. • How “wraparound programs” simplify post-prescription chaos and actually improve outcomes. • The rise of the Chief Customer Experience Officer in pharma… and why it's long overdue.

Pharma is toxic and supplements are natural, right? Let's take a closer look. Get Take Daily HERE. LINKS AND RESOURCES: Watch Video Version Here: Rumble Video Bitchute Video Youtube Video-...

In this eye-opening episode, we take a closer look at two health concerns hiding in plain sight — the radiation risks of medical imaging in children and the hidden heavy metals lurking in popular protein supplements.First, we unpack the latest research on how diagnostic imaging — from CT scans to X-rays — can increase long-term cancer risks for kids. Then, we switch gears to the fitness world to ask: Is your protein shake as clean as you think it is? You might be surprised by what recent lab tests have found.www.georgebatista.com

On this Salcedo Storm Podcast: Chris and Sean talk shutdown and various impacts across Ameirca. Will Ameircans connect the dots about the dangers of all-powerful government? 

Why does it take ten years to bring a new medicine to market, and how can we reduce that number? In this episode of Talking Digital Industries, host Alex Chavez dives into the future of pharma and life sciences with Siobhan Fleming, Solution Owner for Digital Lab at Siemens; Andy Whytock, Pharma Expert at Siemens; and Sean Ruane, Principal Data Scientist at the Medicines Manufacturing Innovation Center. Discover how Siemens' Enterprise Recipe Management and AI-driven lab technologies are helping reduce development timelines, improve sustainability, and, in this case, to bring life-saving treatments to patients faster with the Digital Twin and AI.

Today, we're thrilled to talk to husband-and-wife dream team, Laurie & John Masiello. The Masiellos have been launching and scaling life science companies together since 1984. After merging their first company, Masy BioServices, with a North Carolina CDMO in 2021, the Masiellos struck again, forming Predictive Monitor in 2022. Their debut product, OverShield, combines IoT sensor technology with AI and data analysis to offer a powerful early warning system for controlled GMP chambers, from freezers to cold and stability rooms. The couple's mission centers around harnessing Pharma 4.0 technology to maximize equipment uptime, improve operational efficiency, and protect life-saving biopharmaceutical products.Hear Laurie & John walk us through their incredible shared journey and industry insights as they prepare to celebrate their 50th wedding anniversary.https://www.linkedin.com/company/predictive-monitor-llc/ Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über wacklige KI-Börsen, den neuen Plan für Siemens Healthineers und was diese Woche sonst noch wichtig wird. Außerdem geht es um Palantir, Nvidia, Meta, Microsoft, ASML, SAP, Infineon, Volkswagen, Siemens, Altair, Rumble, Northern Data, Merck & Co., Amgen, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, Novo Nordisk, Eli Lilly, Robinhood und Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

- Brighteon Broadcast News Introduction and AI Revolution Interview (0:10) - Collapse of Human Doctors and Pharmaceutical Industry (1:51) - Trump's Announcement and AI Replacements (11:06) - Economic Collapse and AI Solutions (12:06) - Replacing Congress with AI Agents (34:46) - AI Capabilities and Public Perception (52:28) - The Future of AI and Human Knowledge (1:23:58) - Psychological Barriers and Humility in AI Interaction (1:25:23) - The Future of the Book Industry (1:28:17) - Customization and Personalization in AI (1:35:16) - Advancements in AI and Human Cognition (1:36:27) - Investing in Personal Growth and Skills (1:40:16) - Decentralization and Privacy in AI (1:48:27) - The Role of AI in Personal and Professional Development (1:57:17) - The Future of AI and Robotics (2:07:23) - The Global Race in AI and Technological Advancements (2:10:21) - The Impact of AI on Employment and Society (2:18:24) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today The Chicks talk about everything from a Big Pharma exec collapsing during Trump's presser in the Oval Office to Kennedy's bold plan to cut Congress's pay during a shutdown. Meanwhile, Pelosi's retirement, Rand Paul's defiance, and MTG's throwbacks bring the heat.Plus: Tucker's Fuentes backlash, Islam's spread across Texas and NYC, and Gen Z's disturbing defense of socialist Rep. Mamdani. This episode covers all the insanity — from “fat privilege” to fake ICE stories, liberal TikTok meltdowns, and a viral reporter trying to shame Sydney Sweeney.SUPPORT OUR SPONSORS TO SUPPORT OUR SHOW!Become a premium member of the Angel Guild at https://Angel.com/Chicks to stream YoungDavid today and get two free tickets to see David in theaters this Christmas.Take advantage of Prolon's limited-time offer—get 15% off sitewide plus a $40 bonus gift whenyou subscribe to their 5-Day Program at https://Prolonlife.com/CHICKSNourish your hair, skin, and nails with HealthyCell's Vibrant Hair, Skin & Nails—get 20% off your first order at https://HealthyCell.com/CHICKS with promo code CHICKS.Whatever fall throws at you, make sure you're prepared—visit https://ReadyWise.com and use codeCHICKS10 for 10% off your order today!

Unfortunately, staffing shortages as a result of the government shutdown will affect SeaTac airport. Trump announced a new deal with pharma companies to reduce the price of weight loss drugs. // Seattle Indivisible calls for boycott of Microsoft Game Pass for not condemning a meme it didn’t create. // Washington classrooms are increasingly using AI.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. What it means for the space, and how it could change medicare coverage of the weight loss drugs.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Subscribe to the video podcast: https://www.youtube.com/@LiveHolPlus/podcastsMental health is not a simple checklist, it is a whole body story. In this hol+ episode, Dr. Taz sits down with Dr. James Greenblatt, a pioneer of integrative and nutritional psychiatry, to rethink how we approach depression, anxiety, ADHD, and eating disorders through labs, nutrients, hormones, and personalized care.Together, they unpack why so much suffering persists despite more medications, how root cause testing changes outcomes, and why simple shifts like correcting vitamin D, B12, iron, thyroid, zinc, and omega 3 can transform mood and resilience. They also explore nutrigenomics for precision dosing, the real limits of 10 minute telehealth med checks, and where tools like ketamine, psychedelics, and lithium orotate fit only after foundations are in place.From practical lab targets and cost effective protocols to the crossroads of food, sleep, screens, and ADHD, this conversation invites us to see mental health not as a diagnosis to medicate, but as a system to understand and support.Dr. Taz and Dr. Greenblatt discuss:The gap between symptom focused care and root cause testingKey labs for mood, vitamin D, B12, iron, thyroid, hormonesWhy micronutrients come first for eating disordersMTHFR, methylfolate, glutathione, and antidepressant responseNutrigenomics for personalized vitamin and mineral dosingThe risks of quick med stacking and 10 minute checksWhere ketamine, psychedelics, and lithium orotate may help, and when they do notADHD, ultra processed foods, sugary drinks, sleep, and screen timeAbout Dr. James Greenblatt, MDDr. James Greenblatt, MD is a board certified psychiatrist and a pioneer of integrative and nutritional psychiatry. For more than three decades he has treated patients with ADHD, depression, anxiety, and eating disorders using personalized protocols that combine conventional care with targeted nutrients and lab guided precision. He is the author of multiple books including Finally Focused and the upcoming Finally Hopeful.Connect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.Get your copy of The Hormone Shift: Balance Your Body and Thrive Through Midlife and MenopauseStay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram:https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Follow Dr. James Greenblatt MD: Website: https://jamesgreenblattmd.com Platform: https://PsychiatryRedefined.org Instagram: https://instagram.com/psychiatry_redefinedDon't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+00:00 Introduction, testing gap and the B12 tragedy01:31 Pharma model and 10 minute med checks02:37 Framing the crisis and why patients feel stuck05:49 How psychiatry arrived at symptom based meds07:29 What to test, hormones and core nutrients10:49 The Whole Body Map explained12:39 Vitamin D, B12, iron, thyroid, practical targets17:52 Why meds fail without nutrition18:23 Eating disorders, zinc, omega 3, methylfolate24:33 MTHFR, folate, and glutathione26:34 Nutrigenomics and personalized dosing29:51 Ketamine and psychedelics, proceed with caution32:26 Lithium orotate, irritability and dementia research38:57 Polypharmacy, slowing down, doing the work43:21 ADHD, diet, sleep, screens, lifestyle links46:28 Where to learn more, resources, closing (00:00) - Chapter 1 (00:00) - Introduction, testing gap and the B12 tragedy (01:31) - Pharma model and 10 minute med checks (02:37) - Framing the crisis and why patients feel stuck (05:49) - How psychiatry arrived at symptom based meds (07:29) - What to test, hormones and core nutrients (10:49) - The Whole Body Map explained (12:39) - Vitamin D, B12, iron, thyroid, practical targets (17:52) - Why meds fail without nutrition (18:23) - Eating disorders, zinc, omega 3, methylfolate (24:33) - MTHFR, folate, and glutathione (26:34) - Nutrigenomics and personalized dosing (29:51) - Ketamine and psychedelics, proceed with caution (32:26) - Lithium orotate, irritability and dementia research (38:57) - Polypharmacy, slowing down, doing the work (43:21) - ADHD, diet, sleep, screens, lifestyle links (46:28) - Where to learn more, resources, closing

Host Nate Kaufman brings Rich Helppie back for a discussion about healthcare access.  A 30-day wait for a first oncology visit after hearing the word leukemia is not an edge case—it's the new normal in a system where demand outpaces supply and incentives reward the wrong behaviors. Nate opens with a personal story that reveals how access feels when the stakes are life and death, then pulls back the lens to explain why it happens: a 12-year training pipeline for specialists, uneven reimbursement that pushes clinicians toward concierge and direct primary care, and payer tactics that encourage consolidation rather than capacity.Kaufman and Helppie then get specific about the economics. Medicaid rates that barely cover overhead lead practices to cap panels, while insurers play separate groups against each other until they merge, gaining leverage but not necessarily improving availability. Primary care, which should function like a straightforward retail experience, is instead forced through insurance mechanics that add friction to simple, high-value services. The result is predictable: over 40 percent of ER visits come from Medicaid patients who couldn't access timely outpatient care, and the most vulnerable pay the highest price in avoidable emergencies.Their conversation wrestles with the big numbers and the real trade offs. Ten percent of patients drive more than 80 percent of spending across Medicare and commercial plans. Pharma's incentives to expand lifelong demand clash with insurers' incentives to deny care. The federal government, the largest health benefits organization in the world, changes leadership every few years, making long-term workforce planning and access expansion difficult. They outline pragmatic moves that can help now: secure continuity with direct primary care or concierge if possible, build a relationship with a PCP who can open specialist doors, and for complex care, shop outcomes rather than prices.If you've felt the squeeze—months-long waits, denials, or a scramble for appointments—this conversation gives language, data, and practical options. Listen to understand why access is collapsing, what levers could ease the pressure, and how to protect your path to timely, high-quality care today. If the ideas resonate, follow and share, and leave a review with your own access story—what worked, what didn't, and what needs to change next.Support the showEngage the conversation on Substack at The Common Bridge!

PODCAST LAS NOTICIAS CON CALLE DE 3 DE NOVIEMBRE 2025 -  NO DE TRUMP A LA ESTADIDAD para PR - Truth TRUMP echa pa atrás y ahora dice que quiere pagar SNAP y cupones - Truth Sigue siendo delito asesinato de mujeres, solo hay polémica sobre se llama feminicidio o no - Primera Hora Demotion o no para secretario de Agricultura - El Nuevo Día Baja a votación ley para eliminar escoltas a futuros gobernadores Gobernadora vuelve a nombrar otro comité ahora para impuesto del inventario - El Nuevo DíaPresupuesto ha sido ideológico no ha sido real austeridad - El Nuevo DíaGobernadora dice que su logro y su meta es … CESCO DIGITAL, pero en otras agencias - El Nuevo Día Negocian para contrato de Gas Natural con la Junta y la gobernadora - El Nuevo Día Ya Energiza nos dice que no va a ser más caro el costo de su planta y que van para finales de la década- El Nuevo Día ¿Vale la pena meterle tanto dinero a incentivar big Pharma cuando ya no crea los empleos que antes? - Cuarto Poder Niño tira petardo mientras camión echaba gasolina, lo buscan a él y a su madre - WUNORecortan dinero para cuidado histórico - El Nuevo día Familia de la gobernadora dice que no hay investigación sobre casa de la Parguera - El NuevoDía Turista de Chicago alega que tres mujeres le echaron algo en bebida para robarle Rolex y otras pertenencias - Primera HoraLa contralora pide poderes - El Nuevo DíaHarán pruebas nucleares, sin hacer explosiones dicen jefe de energía federal - NyT Trump dice no a tomahawks para Ucrania, por ahora, aunque Dpto de Guerra había dicho que sí - Reuters Trump considera meterle ejército a Nigeria por genocidio de cristianos - WSJTrump insiste en acabar con el filibusterismo para reabrir el gobierno federal  - Truth Llegó el momento de las arañitas a Martins BBQ! Pide el mejor y más sabroso pollo asado a la vara de Puerto Rico en combo con arañitas de plátano…fresquecitas, acabaditas de hacer en Martin 's BBQ, Justo como te gusta!  Entregando con Ubereats y Doordash en tiendas participantes,Pide tus arañitas en MMMMartins BBQ comida fresca, hecha todos los dias.Asado, Jugoso, Sabroso..hoy voy pa Martins bbqIncluye auspicio 

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the weight loss wars, and the other pharma stocks moving on potential M&A action.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

- Improvements in Sensor Dot News and AI Engine (0:10) - Demonstration of AI-Generated News Content (3:16) - Development and Impact of Brighteon.ai (6:55) - Introduction of Grokipedia and Naturalpedia (9:46) - Challenges and Future Plans for AI Projects (14:03) - Launch of Vaccine Forensics Website (24:24) - Features and Capabilities of Vaccine Forensics (31:36) - Importance of Independent Media and AI Engines (44:25) - Special Reports on UBI and Food Riots (57:35) - Food Stamp Program and Its Impact on Society (1:20:38) - Political Benefits and Potential Violence (1:25:05) - Economic and Social Consequences (1:33:51) - Preparation and Safety Measures (1:38:28) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com